Julia I. Medina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Julia I. Medina has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Cornelis P. Vlaar
Department of Pharmaceutical Sciences, University of Puerto Rico, Medical Sciences Campus, San Juan, PR 00936, United States
33 shared publications - Suranganie Dharmawardhane
Department of Biochemistry, School of Medicine, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico
33 shared publications - Eliud Hernandez O'Farril
University of Puerto Rico, Medical Sciences Campus, School of Pharmacy, San Juan, PR
24 shared publications - Ailed Cruz-Collazo
Department of Biochemistry, School of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
22 shared publications - Luis Daniel Borrero‐Garcia
Division of Clinical and Translational Cancer Research, University of Puerto Rico Comprehensive Cancer Center, San Juan 00921, Puerto Rico
21 shared publications - Marcelo G. Kazanietz
Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine , Miami, FL 33136
21 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Data from M6 Metabolite Contributes to the Efficacy of the Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Breast Cancer
Metastasis remains a major challenge in cancer treatment because of the lack of effective targeted therapies. MBQ-167, a first-in-class dual Rac/Cdc42 inhibitor currently in a phase I clinical trial, has demonstrated promising activity in preclinical breast cancer models by reducing tumor burden and preventing metastasis. To characterize its metabolism, we conducted liver microsome assays and identified several MBQ-167 metabolites. Of these, M6 was the primary metabolite from dog and human plasma following oral administration of MBQ-167. The M6cpharmacokinetics profile parallels that of MBQ-167 in human plasma from patients with advanced breast cancer enrolled in the clinical trial. In metastatic breast cancer cell lines (HER2-BM, MDA-MB-231, and MDA-MB-468), M6 exhibited minimal effects on cell viability and apoptosis but strongly inhibited Rac1 activation without affecting Cdc42 activation. M6 also inhibited phosphorylation of group 1 p21-activated kinases (PAK) more effectively than MBQ-167 and significantly reduced breast cancer cell migration in wound healing and Transwell assays. In vivo studies with immunocompromised mice bearing HER2-BM tumors demonstrated that M6 inhibits tumor growth and metastasis to the lungs, livers, and kidneys by ∼90%, comparable with MBQ-167. These findings suggest that M6 exhibits potent anticancer properties both in vitro and in vivo, potentially contributing to the sustained efficacy of MBQ-167 in metastatic breast cancer.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from M6 Metabolite Contributes to the Efficacy of the Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Breast Cancer
Metastasis remains a major challenge in cancer treatment because of the lack of effective targeted therapies. MBQ-167, a first-in-class dual Rac/Cdc42 inhibitor currently in a phase I clinical trial, has demonstrated promising activity in preclinical breast cancer models by reducing tumor burden and preventing metastasis. To characterize its metabolism, we conducted liver microsome assays and identified several MBQ-167 metabolites. Of these, M6 was the primary metabolite from dog and human plasma following oral administration of MBQ-167. The M6cpharmacokinetics profile parallels that of MBQ-167 in human plasma from patients with advanced breast cancer enrolled in the clinical trial. In metastatic breast cancer cell lines (HER2-BM, MDA-MB-231, and MDA-MB-468), M6 exhibited minimal effects on cell viability and apoptosis but strongly inhibited Rac1 activation without affecting Cdc42 activation. M6 also inhibited phosphorylation of group 1 p21-activated kinases (PAK) more effectively than MBQ-167 and significantly reduced breast cancer cell migration in wound healing and Transwell assays. In vivo studies with immunocompromised mice bearing HER2-BM tumors demonstrated that M6 inhibits tumor growth and metastasis to the lungs, livers, and kidneys by ∼90%, comparable with MBQ-167. These findings suggest that M6 exhibits potent anticancer properties both in vitro and in vivo, potentially contributing to the sustained efficacy of MBQ-167 in metastatic breast cancer.
- Open Access
- 4 April 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (9) , OF1-OF11
M6 Metabolite Contributes to the Efficacy of the Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Breast Cancer
Metastasis remains a major challenge in cancer treatment because of the lack of effective targeted therapies. MBQ-167, a first-in-class dual Rac/Cdc42 inhibitor currently in a phase I clinical trial, has demonstrated promising activity in preclinical breast cancer models by reducing tumor burden and preventing metastasis. To characterize its metabolism, we conducted liver microsome assays and identified several MBQ-167 metabolites. Of these, M6 was the primary metabolite from dog and human plasma following oral administration of MBQ-167. The M6cpharmacokinetics profile parallels that of MBQ-167 in human plasma from patients with advanced breast cancer enrolled in the clinical trial. In metastatic breast cancer cell lines (HER2-BM, MDA-MB-231, and MDA-MB-468), M6 exhibited minimal effects on cell viability and apoptosis but strongly inhibited Rac1 activation without affecting Cdc42 activation. M6 also inhibited phosphorylation of group 1 p21-activated kinases (PAK) more effectively than MBQ-167 and significantly reduced breast cancer cell migration in wound healing and Transwell assays. In vivo studies with immunocompromised mice bearing HER2-BM tumors demonstrated that M6 inhibits tumor growth and metastasis to the lungs, livers, and kidneys by ∼90%, comparable with MBQ-167. These findings suggest that M6 exhibits potent anticancer properties both in vitro and in vivo, potentially contributing to the sustained efficacy of MBQ-167 in metastatic breast cancer.
- 4 April 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (9) , OF1-OF11
Open AccessM6 Metabolite Contributes to the Efficacy of the Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Breast Cancer
Metastasis remains a major challenge in cancer treatment because of the lack of effective targeted therapies. MBQ-167, a first-in-class dual Rac/Cdc42 inhibitor currently in a phase I clinical trial, has demonstrated promising activity in preclinical breast cancer models by reducing tumor burden and preventing metastasis. To characterize its metabolism, we conducted liver microsome assays and identified several MBQ-167 metabolites. Of these, M6 was the primary metabolite from dog and human plasma following oral administration of MBQ-167. The M6cpharmacokinetics profile parallels that of MBQ-167 in human plasma from patients with advanced breast cancer enrolled in the clinical trial. In metastatic breast cancer cell lines (HER2-BM, MDA-MB-231, and MDA-MB-468), M6 exhibited minimal effects on cell viability and apoptosis but strongly inhibited Rac1 activation without affecting Cdc42 activation. M6 also inhibited phosphorylation of group 1 p21-activated kinases (PAK) more effectively than MBQ-167 and significantly reduced breast cancer cell migration in wound healing and Transwell assays. In vivo studies with immunocompromised mice bearing HER2-BM tumors demonstrated that M6 inhibits tumor growth and metastasis to the lungs, livers, and kidneys by ∼90%, comparable with MBQ-167. These findings suggest that M6 exhibits potent anticancer properties both in vitro and in vivo, potentially contributing to the sustained efficacy of MBQ-167 in metastatic breast cancer.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Structural figures of NAMPT inhibitors.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Structural figures of NAMPT inhibitors.